Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab

Cardona-Mendoza, Andrés FelipeWills, BeatrizArrieta, OscarReguart, NoemiCorrales, LuisOtero, JorgeCuello, MauricioRolfo, ChristianRosell, RafaelZatarain-Barrón, Zyanya LuciaRojas Puentes, LeonardoRuiz-Patiño, AlejandroCarranza Isaza, HernánVargas Báez, Carlos AlbertoMartín, ClaudioPino, Luis Eduardo2020-05-142020-05-1420170250-7005https://hdl.handle.net/20.500.12495/2790application/pdfengSurvival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumabarticleTratamiento farmacológicoCalidad de vidaNeoplasias pulmonaresIrinotecanBevacizumabTIMP1EGFR mutationGene expressionhttps://doi.org/10.21873/anticanres.12097Acceso cerrado2017